JP2015536325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536325A5 JP2015536325A5 JP2015537799A JP2015537799A JP2015536325A5 JP 2015536325 A5 JP2015536325 A5 JP 2015536325A5 JP 2015537799 A JP2015537799 A JP 2015537799A JP 2015537799 A JP2015537799 A JP 2015537799A JP 2015536325 A5 JP2015536325 A5 JP 2015536325A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- pharmaceutically acceptable
- prodrug
- tautomer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 173
- 239000000651 prodrug Substances 0.000 claims description 95
- 229940002612 prodrug Drugs 0.000 claims description 95
- 150000003839 salts Chemical class 0.000 claims description 95
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- -1 amino acid ester Chemical class 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 claims description 5
- 102100034911 Pyruvate kinase PKM Human genes 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 5
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 0 C=*c1cccc(P)c1N Chemical compound C=*c1cccc(P)c1N 0.000 description 5
- CPCWRGPJUDZREC-UHFFFAOYSA-N Cc(cccc1N2)c1SC2=O Chemical compound Cc(cccc1N2)c1SC2=O CPCWRGPJUDZREC-UHFFFAOYSA-N 0.000 description 1
- ABLADXPKDITIOC-UHFFFAOYSA-N Cc1c(c(F)c[nH]2)c2ccc1 Chemical compound Cc1c(c(F)c[nH]2)c2ccc1 ABLADXPKDITIOC-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N Cc1cccc2c1cc[nH]2 Chemical compound Cc1cccc2c1cc[nH]2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- QCXGJTGMGJOYDP-UHFFFAOYSA-N Cc1cccc2c1nc[nH]2 Chemical compound Cc1cccc2c1nc[nH]2 QCXGJTGMGJOYDP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714659P | 2012-10-16 | 2012-10-16 | |
| US61/714,659 | 2012-10-16 | ||
| US201361875855P | 2013-09-10 | 2013-09-10 | |
| US61/875,855 | 2013-09-10 | ||
| PCT/US2013/065296 WO2014062838A2 (en) | 2012-10-16 | 2013-10-16 | Pkm2 modulators and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203963A Division JP6526767B2 (ja) | 2012-10-16 | 2017-10-20 | Ｐｋｍ２調節因子およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536325A JP2015536325A (ja) | 2015-12-21 |
| JP2015536325A5 true JP2015536325A5 (enExample) | 2016-12-01 |
| JP6243918B2 JP6243918B2 (ja) | 2017-12-06 |
Family
ID=50488890
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537799A Active JP6243918B2 (ja) | 2012-10-16 | 2013-10-16 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2017203963A Active JP6526767B2 (ja) | 2012-10-16 | 2017-10-20 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2018186629A Withdrawn JP2019023209A (ja) | 2012-10-16 | 2018-10-01 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2020035657A Withdrawn JP2020097631A (ja) | 2012-10-16 | 2020-03-03 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2020035656A Withdrawn JP2020105190A (ja) | 2012-10-16 | 2020-03-03 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2021120679A Active JP7128331B2 (ja) | 2012-10-16 | 2021-07-21 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2021129580A Pending JP2021181467A (ja) | 2012-10-16 | 2021-08-06 | Ｐｋｍ２調節因子およびそれらの使用方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203963A Active JP6526767B2 (ja) | 2012-10-16 | 2017-10-20 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2018186629A Withdrawn JP2019023209A (ja) | 2012-10-16 | 2018-10-01 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2020035657A Withdrawn JP2020097631A (ja) | 2012-10-16 | 2020-03-03 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2020035656A Withdrawn JP2020105190A (ja) | 2012-10-16 | 2020-03-03 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2021120679A Active JP7128331B2 (ja) | 2012-10-16 | 2021-07-21 | Ｐｋｍ２調節因子およびそれらの使用方法 |
| JP2021129580A Pending JP2021181467A (ja) | 2012-10-16 | 2021-08-06 | Ｐｋｍ２調節因子およびそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US9394257B2 (enExample) |
| EP (1) | EP2909181B1 (enExample) |
| JP (7) | JP6243918B2 (enExample) |
| DK (1) | DK2909181T3 (enExample) |
| ES (1) | ES2644758T3 (enExample) |
| WO (1) | WO2014062838A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2909181B1 (en) * | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| JP6594570B2 (ja) | 2017-03-20 | 2019-10-23 | フォーマ セラピューティクス，インコーポレイテッド | ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物 |
| US20200237766A1 (en) * | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| JP7547360B2 (ja) * | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 |
| US20220162200A1 (en) * | 2019-03-22 | 2022-05-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Pkm2 modulators and methods for their use |
| AU2020350763A1 (en) | 2019-09-19 | 2022-04-07 | Novo Nordisk Health Care Ag | Pyruvate kinase R (PKR) activating compositions |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| JP2861087B2 (ja) * | 1989-08-08 | 1999-02-24 | 三菱化学株式会社 | Ｎ―アシル‐５‐ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| IT1255527B (it) * | 1992-09-29 | 1995-11-09 | Mini Ricerca Scient Tecnolog | Pirazolcarbossammidi ad attivita' insetticida ed acaricida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| MX9708026A (es) | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| DE19600097C1 (de) | 1996-01-03 | 1997-07-31 | Siemens Ag | Verfahren und Vorrichtung zur Bestimmung einer Flüssigkeitshöhe mit Hilfe von Ultraschallimpulsen |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| IL127567A0 (en) | 1996-07-18 | 1999-10-28 | Pfizer | Phosphinate based inhibitors of matrix metalloproteases |
| JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク． | アリールスルホニルアミノヒドロキサム酸誘導体 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| CA2280151C (en) | 1997-02-11 | 2005-12-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| EA002490B1 (ru) | 1997-08-08 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилоксиарилсульфониламиногидроксамовой кислоты |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| BR9814018A (pt) | 1997-11-11 | 2000-09-26 | Pfizer Prod Inc | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| DE69915004T2 (de) | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| JP2001172261A (ja) * | 1999-12-20 | 2001-06-26 | Mitsubishi Chemicals Corp | ピラゾールカルボン酸アミド類、およびこれを有効成分とする殺虫、殺ダニ剤 |
| RS50444B (sr) | 2000-02-15 | 2010-03-02 | Sugen Inc. | Inhibitori 2-indolinon protein kinaze supstituisani pirolom |
| US6960614B2 (en) | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE346064T1 (de) * | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| JP2002363164A (ja) * | 2001-04-06 | 2002-12-18 | Mitsubishi Chemicals Corp | ピラゾールカルボキサミド類、その中間体およびこれを有効成分とする有害生物防除剤 |
| US20050085524A1 (en) * | 2001-04-06 | 2005-04-21 | Nihon Nohyaku Co,. Ltd. | Pyrazolecarboxamides, intermediates therefor and pest control agent comprising the same as active ingredients |
| NZ535101A (en) | 2002-03-08 | 2007-07-27 | Eisai Co Ltd | Macrocyclic compounds useful as pharmaceuticals |
| MXPA04008893A (es) | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| AU2006231917B2 (en) | 2005-04-08 | 2011-07-28 | Pfizer Products Inc. | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors |
| BRPI0609464A2 (pt) * | 2005-05-23 | 2010-04-13 | Japan Tobacco Inc | composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo |
| CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2009025781A1 (en) | 2007-08-16 | 2009-02-26 | Beth Israel Deaconess Medical Center | Activators of pyruvate kinase m2 and methods of treating disease |
| WO2009028280A1 (ja) * | 2007-08-29 | 2009-03-05 | Mitsui Chemicals, Inc. | ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤 |
| JP5658565B2 (ja) | 2007-09-12 | 2015-01-28 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法 |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| CA3041868C (en) * | 2008-10-09 | 2023-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase |
| US8637550B2 (en) | 2008-11-17 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Heteroaryl diamide compounds useful as MMP-13 inhibitors |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| JP5756457B2 (ja) * | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| CA2760929C (en) | 2009-05-04 | 2018-01-02 | Agios Pharmaceuticals, Inc. | Pkm2 activators for use in the treatment of cancer |
| US8349832B2 (en) | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| WO2012041256A1 (en) | 2010-09-30 | 2012-04-05 | Chi-Ying Huang | Anti-cancer extract and compounds |
| EP2632920A1 (en) | 2010-10-27 | 2013-09-04 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of pkm2 |
| WO2012083246A1 (en) * | 2010-12-17 | 2012-06-21 | Agios Pharmaceuticals, Inc. | Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| MX336022B (es) | 2010-12-21 | 2016-01-06 | Agios Pharmaceuticals Inc | Activadores de pkm2 bicíclicos. |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| EP2497775A1 (en) | 2011-03-11 | 2012-09-12 | Ruprecht-Karls-Universität Heidelberg | Ferrocene-based compounds and their use as ROS regulating prodrugs |
| US20120302609A1 (en) * | 2011-05-25 | 2012-11-29 | Dynamix Pharmaceuticals Ltd. | Pyrazolines for the Modulation of PKM2 |
| WO2013005157A1 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer |
| EP2909181B1 (en) * | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| KR20150080619A (ko) | 2012-11-08 | 2015-07-09 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 화합물 및 조성물 |
| US9447054B2 (en) | 2014-01-15 | 2016-09-20 | Korea Institute Of Radiological & Medical Sciences | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient |
-
2013
- 2013-10-16 EP EP13847643.7A patent/EP2909181B1/en active Active
- 2013-10-16 DK DK13847643.7T patent/DK2909181T3/da active
- 2013-10-16 JP JP2015537799A patent/JP6243918B2/ja active Active
- 2013-10-16 ES ES13847643.7T patent/ES2644758T3/es active Active
- 2013-10-16 US US14/435,976 patent/US9394257B2/en active Active
- 2013-10-16 WO PCT/US2013/065296 patent/WO2014062838A2/en not_active Ceased
-
2016
- 2016-06-15 US US15/183,581 patent/US10207996B2/en active Active
-
2017
- 2017-10-20 JP JP2017203963A patent/JP6526767B2/ja active Active
-
2018
- 2018-10-01 JP JP2018186629A patent/JP2019023209A/ja not_active Withdrawn
- 2018-12-19 US US16/226,599 patent/US10472328B2/en active Active
-
2019
- 2019-09-26 US US16/584,912 patent/US10766865B2/en active Active
-
2020
- 2020-03-03 JP JP2020035657A patent/JP2020097631A/ja not_active Withdrawn
- 2020-03-03 JP JP2020035656A patent/JP2020105190A/ja not_active Withdrawn
- 2020-07-15 US US16/930,254 patent/US20210002233A1/en not_active Abandoned
-
2021
- 2021-07-21 JP JP2021120679A patent/JP7128331B2/ja active Active
- 2021-08-06 JP JP2021129580A patent/JP2021181467A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536325A5 (enExample) | ||
| JP2016501185A5 (enExample) | ||
| JP2016506369A5 (enExample) | ||
| NZ721534A (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| JP2018501215A5 (enExample) | ||
| JP2016506368A5 (enExample) | ||
| JP2016518324A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| JP2016530283A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| NZ631762A (en) | 5-membered heteroaryls and their use as antiviral agents | |
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| JP2016519653A5 (enExample) | ||
| EP3954679A3 (en) | Amide compounds for the treatment of hiv infections | |
| JP2018533611A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
| JP2016514159A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| PH12017500111A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| IN2014MN02658A (enExample) | ||
| JP2013537203A5 (enExample) |